Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.4 EUR | -.--% | +1.33% | -5.32% |
Apr. 22 | Lists in green except Mib; banks good | AN |
Apr. 22 | Iveco down on Mib; European stock exchanges in green | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The firm trades with high earnings multiples: 28.51 times its 2024 earnings per share.
- With an enterprise value anticipated at 4.41 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.32% | 548M | C | ||
+33.25% | 699B | C+ | ||
+28.59% | 571B | B | ||
-3.55% | 364B | C+ | ||
+18.16% | 326B | B- | ||
+4.36% | 286B | C+ | ||
+14.81% | 236B | B+ | ||
+4.93% | 198B | B- | ||
-9.78% | 194B | A+ | ||
-3.69% | 149B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PHN Stock
- Ratings Pharmanutra S.p.A.